Antios Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Antios Therapeutics's estimated annual revenue is currently $930k per year.
- Antios Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Antios Therapeutics has 6 Employees.
- Antios Therapeutics grew their employee count by -73% last year.
Antios Therapeutics's People
| Name | Title | Email/Phone |
|---|
Antios Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $1.7M | 11 | -8% | N/A | N/A |
#3 | $2.3M | 15 | 50% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $17.1M | 110 | 5% | $0.07B | N/A |
#6 | $4M | 26 | -7% | N/A | N/A |
#7 | $0.8M | 5 | 0% | N/A | N/A |
#8 | $1.1M | 7 | 17% | N/A | N/A |
#9 | $7.8M | 50 | 2% | N/A | N/A |
#10 | $1.7M | 11 | 10% | N/A | N/A |
What Is Antios Therapeutics?
Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.
keywords:N/A
N/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-73%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Antios Therapeutics News
2022-04-06 - Clinical Catch-Up: Adagio to Seek COVID-19 EUA, CytoDyn's ...
The drug is a first-in-class, non-opioid, long-lasting therapeutic. Antios Therapeutics reported new data from the Phase Ib and IIa trials of...
2022-03-30 - Antios Therapeutics' ATI-2173 Demonstrates Suppression of ...
Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral...
Other Companies in Atlanta
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.1M | 6 | -45% | $57.7M |
#2 | $0.6M | 6 | 0% | N/A |
#3 | $0.4M | 6 | N/A | N/A |
#4 | $0.4M | 6 | N/A | N/A |
#5 | $0.4M | 6 | N/A | N/A |